Vardenafil hydrochloride

Vardenafil hydrochloride (CAS No.: 224785-91-5) is a synthetic small molecule phosphodiesterase inhibitor in the PDE5 focused research category, widely used as a pharmacological tool in biomedical investigation of cyclic nucleotide signaling, where it acts as a highly potent and selective inhibitor of PDE5 with activity in the subnanomolar range and shows comparatively weaker inhibition of related isoforms such as PDE6 and PDE1 in the low to mid nanomolar range and minimal activity against PDE3 and PDE4 at substantially higher concentrations, consistent with a selectivity profile that supports mechanistic interrogation of cGMP regulated pathways; functionally, this compound suppresses cGMP hydrolysis in a noncompetitive manner and elevates intracellular cGMP tone, thereby enabling controlled study of downstream signaling modules including protein kinase G dependent processes, nitric oxide cGMP axis dynamics, and vascular or metabolic response networks in experimental systems; in vitro studies commonly employ concentration windows spanning nanomolar to low micromolar levels according to assay format, target expression, and endpoint sensitivity, while in vivo preclinical studies use protocol dependent dosing schemes selected to match pharmacodynamic objectives and model constraints; in life sciences and drug discovery workflows, vardenafil hydrochloride is primarily applied in target validation, pathway deconvolution, comparative isoform selectivity testing, and reference benchmarking in cell based assays and animal models relevant to vascular biology, hepatic and metabolic dysfunction research, and broader phosphodiesterase focused screening programs, with concentrations or doses used in experiments typically determined by specific experimental designs and research objectives.